This includes genomic analysis such as TP53 mutations in breast cancer cells (27), APC mutations in colorectal cancer (36), targeted mutational panels in prostate (31) and lung cancer (33); and single-cell RNA sequencing as demonstrated in breast cancer (29). Here, TP53 is linked to lung carcinoma.